Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.

Leukemia & lymphoma - 1 Dec 2017

Chuzi Sarah, Stein Brady L

Abstract excerpt

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that is associated with diminished quality of life, thrombohemorrhagic complications, and transformation to myelofibrosis (MF) and acute leukemia (AML). The important recent discoveries of driver mutations, including the calreticulin gene in addition to JAK2 and MPL, have led to a greater understanding of disease pathogenesis and set the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Disease Progression

Share to Genetic Association Studies

Share to Genetic Predisposition to Disease

Share to Prognosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 28503969
DOI: 10.1080/10428194.2017.1312371

Genes

JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.PMID 28503969Read ↗

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Semantic proximity Read ↗

Calreticulin mutations in essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.Semantic proximity Read ↗

A rare CALR variant mutation and a review of CALR in essential thrombocythemia.Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

Myeloproliferative Neoplasms: A Contemporary Review.Semantic proximity Read ↗

New advances in the pathogenesis and therapy of essential thrombocythemia.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

Two faces of ET: CALR and JAK2.Semantic proximity Read ↗

Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.Semantic proximity Read ↗

Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.